http://www.amtbiopharma.com/news/154/182/Amsterdam-Molecular-Therapeutics-Reports-Full-Year-Results-2011.html Amsterdam Molecular Therapeutics Reports Full Year Results 2011 ... Fri, 27 Apr 2012 08:45:42 +0000 http://www.amtbiopharma.com/news/154/182/Amsterdam-Molecular-Therapeutics-Reports-Full-Year-Results-2011.html http://www.amtbiopharma.com/news/153/182/Overview-of-key-transaction-elements-and-timetable-with-regard-to-the-public-to-private-and-financing-transaction-between-AMT-and-uniQure-BV.html Overview of key transaction elements and timetable with regard to the public-to-private and financing transaction between AMT and uniQure BV ... Thu, 26 Apr 2012 18:57:35 +0000 http://www.amtbiopharma.com/news/153/182/Overview-of-key-transaction-elements-and-timetable-with-regard-to-the-public-to-private-and-financing-transaction-between-AMT-and-uniQure-BV.html http://www.amtbiopharma.com/news/152/182/Amsterdam-Molecular-Therapeutics-completes-advance-distribution-of-uniQure-depositary-receipts-to-AMT-shareholders.html Amsterdam Molecular Therapeutics completes advance distribution of uniQure depositary receipts to AMT shareholders ... Thu, 26 Apr 2012 16:54:07 +0000 http://www.amtbiopharma.com/news/152/182/Amsterdam-Molecular-Therapeutics-completes-advance-distribution-of-uniQure-depositary-receipts-to-AMT-shareholders.html http://www.amtbiopharma.com/news/150/182/Amsterdam-Molecular-Therapeutics-Receives-Further-Opinion-on-Glybera-Marketing-Authorisation-Application.html Amsterdam Molecular Therapeutics Receives Further Opinion on Glybera® Marketing Authorisation Application ... Mon, 23 Apr 2012 11:50:30 +0000 http://www.amtbiopharma.com/news/150/182/Amsterdam-Molecular-Therapeutics-Receives-Further-Opinion-on-Glybera-Marketing-Authorisation-Application.html http://www.amtbiopharma.com/news/151/182/Amsterdam-Molecular-Therapeutics-reconfirms-timetable-of-principle-events-of-its-liquidation-process.html Amsterdam Molecular Therapeutics reconfirms timetable of principle events of its liquidation process ... Tue, 17 Apr 2012 07:56:14 +0000 http://www.amtbiopharma.com/news/151/182/Amsterdam-Molecular-Therapeutics-reconfirms-timetable-of-principle-events-of-its-liquidation-process.html http://www.amtbiopharma.com/news/149/182/Amsterdam-Molecular-Therapeutics-announces-completion-of-disposal-of-its-operations-to-uniQure-B-V-and-its-dissolution-becoming-effective.html Amsterdam Molecular Therapeutics announces completion of disposal of its operations to uniQure B.V. and its dissolution becoming effective ... Fri, 06 Apr 2012 06:00:00 +0000 http://www.amtbiopharma.com/news/149/182/Amsterdam-Molecular-Therapeutics-announces-completion-of-disposal-of-its-operations-to-uniQure-B-V-and-its-dissolution-becoming-effective.html http://www.amtbiopharma.com/news/148/182/Amsterdam-Molecular-Therapeutics-Announces-Results-of-Extraordinary-General-Meeting.html Amsterdam Molecular Therapeutics Announces Results of Extraordinary General Meeting ... Fri, 30 Mar 2012 13:16:11 +0000 http://www.amtbiopharma.com/news/148/182/Amsterdam-Molecular-Therapeutics-Announces-Results-of-Extraordinary-General-Meeting.html http://www.amtbiopharma.com/news/147/182/Amsterdam-Molecular-Therapeutics-Publishes-Positive-Data-from-Glybera-14-Week-Study.html Amsterdam Molecular Therapeutics Publishes Positive Data from Glybera® 14 Week Study ... Wed, 28 Mar 2012 17:31:53 +0000 http://www.amtbiopharma.com/news/147/182/Amsterdam-Molecular-Therapeutics-Publishes-Positive-Data-from-Glybera-14-Week-Study.html http://www.amtbiopharma.com/news/144/182/Proxy-for-the-EGM-to-be-held-on-30-March-2012.html Proxy for the EGM to be held on 30 March 2012 ... Thu, 15 Mar 2012 14:20:00 +0000 http://www.amtbiopharma.com/news/144/182/Proxy-for-the-EGM-to-be-held-on-30-March-2012.html http://www.amtbiopharma.com/news/145/182/Invitation-to-informational-meeting-March-20-2012.html Post the announcement of AMT being acquired by uniQure BV, we invite you to an informational meeting on the transaction. ... Thu, 15 Mar 2012 13:30:22 +0000 http://www.amtbiopharma.com/news/145/182/Invitation-to-informational-meeting-March-20-2012.html http://www.amtbiopharma.com/news/143/182/uniQure-Q-A.html uniQure Q&A ... Thu, 08 Mar 2012 17:00:00 +0000 http://www.amtbiopharma.com/news/143/182/uniQure-Q-A.html http://www.amtbiopharma.com/news/142/182/Amsterdam-Molecular-Therapeutics-Receives-Request-for-Further-Information-from-CHMP-on-Glybera.html Amsterdam Molecular Therapeutics Receives Request for Further Information from CHMP on Glybera® ... Mon, 20 Feb 2012 23:00:00 +0000 http://www.amtbiopharma.com/news/142/182/Amsterdam-Molecular-Therapeutics-Receives-Request-for-Further-Information-from-CHMP-on-Glybera.html http://www.amtbiopharma.com/news/140/182/Invitation-to-informational-meeting-February-23-2012.html Post the announcement of AMT being acquired by uniQure BV, we invite you to an informational meeting on the transaction. ... Mon, 20 Feb 2012 22:48:19 +0000 http://www.amtbiopharma.com/news/140/182/Invitation-to-informational-meeting-February-23-2012.html http://www.amtbiopharma.com/news/138/182/Amsterdam-Molecular-Therapeutics-Business-to-be-Acquired-by-uniQure-BV.html Amsterdam Molecular Therapeutics Business to be Acquired by uniQure BV ... Fri, 17 Feb 2012 06:00:00 +0000 http://www.amtbiopharma.com/news/138/182/Amsterdam-Molecular-Therapeutics-Business-to-be-Acquired-by-uniQure-BV.html http://www.amtbiopharma.com/news/137/182/Amsterdam-Molecular-Therapeutics-Announces-European-Commission-Delays-Decision-on-Glybera-Marketing-Authorisation-And-Requests-Further-Information-From-the-CHMP.html Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing... ... Mon, 30 Jan 2012 07:00:00 +0000 http://www.amtbiopharma.com/news/137/182/Amsterdam-Molecular-Therapeutics-Announces-European-Commission-Delays-Decision-on-Glybera-Marketing-Authorisation-And-Requests-Further-Information-From-the-CHMP.html http://www.amtbiopharma.com/news/132/182/Amsterdam-Molecular-Therapeutics-Receives-US-Orphan-Designation-for-Hemophilia-B-Gene-Therapy.html Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy ... Wed, 04 Jan 2012 06:00:00 +0000 http://www.amtbiopharma.com/news/132/182/Amsterdam-Molecular-Therapeutics-Receives-US-Orphan-Designation-for-Hemophilia-B-Gene-Therapy.html http://www.amtbiopharma.com/news/131/182/Amsterdam-Molecular-Therapeutics-Announces-2-5-Million-Equity-Raise.html Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise ... Fri, 30 Dec 2011 11:10:16 +0000 http://www.amtbiopharma.com/news/131/182/Amsterdam-Molecular-Therapeutics-Announces-2-5-Million-Equity-Raise.html http://www.amtbiopharma.com/news/130/182/Amsterdam-Molecular-Therapeutics-Announces-Negative-Equity-Position.html Amsterdam Molecular Therapeutics Announces Negative Equity Position ... Thu, 15 Dec 2011 06:00:00 +0000 http://www.amtbiopharma.com/news/130/182/Amsterdam-Molecular-Therapeutics-Announces-Negative-Equity-Position.html http://www.amtbiopharma.com/news/129/182/Amsterdam-Molecular-Therapeutics-Provides-Business-Update-for-the-Third-Quarter-2011.html Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011 ... Thu, 17 Nov 2011 06:00:00 +0000 http://www.amtbiopharma.com/news/129/182/Amsterdam-Molecular-Therapeutics-Provides-Business-Update-for-the-Third-Quarter-2011.html http://www.amtbiopharma.com/news/128/182/Amsterdam-Molecular-Therapeutics-Receives-Orphan-Designation-in-the-European-Union-for-Hemophilia-B-Gene-Therapy.html Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy ... Wed, 16 Nov 2011 06:00:00 +0000 http://www.amtbiopharma.com/news/128/182/Amsterdam-Molecular-Therapeutics-Receives-Orphan-Designation-in-the-European-Union-for-Hemophilia-B-Gene-Therapy.html http://www.amtbiopharma.com/news/135/182/Amsterdam-Molecular-Therapeutics-Provides-Operations-Update-and-Strategic-Review-of-Pipeline.html Amsterdam Molecular Therapeutics Provides Operations Update and Strategic Review of Pipeline ... Tue, 25 Oct 2011 15:46:01 +0000 http://www.amtbiopharma.com/news/135/182/Amsterdam-Molecular-Therapeutics-Provides-Operations-Update-and-Strategic-Review-of-Pipeline.html http://www.amtbiopharma.com/news/57/182/Amsterdam-Molecular-Therapeutics-Receives-Opinion-on-Re-examination-of-Glybera-Marketing-Authorisation.html Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation ... Fri, 21 Oct 2011 14:14:08 +0000 http://www.amtbiopharma.com/news/57/182/Amsterdam-Molecular-Therapeutics-Receives-Opinion-on-Re-examination-of-Glybera-Marketing-Authorisation.html http://www.amtbiopharma.com/news/52/182/October-7-2011---Company-visit-AMT.html Uitnodiging company visit AMT ... Fri, 07 Oct 2011 07:02:14 +0000 http://www.amtbiopharma.com/news/52/182/October-7-2011---Company-visit-AMT.html http://www.amtbiopharma.com/news/43/182/Amsterdam-Molecular-Therapeutics-Reports-Half-Year-Results-2011.html Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 ... Thu, 25 Aug 2011 14:43:57 +0000 http://www.amtbiopharma.com/news/43/182/Amsterdam-Molecular-Therapeutics-Reports-Half-Year-Results-2011.html http://www.amtbiopharma.com/news/30/182/Amsterdam-Molecular-Therapeutics-Files-Glybera-European-Marketing-Application-for-Re-examination.html Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination ... Fri, 08 Jul 2011 08:30:37 +0000 http://www.amtbiopharma.com/news/30/182/Amsterdam-Molecular-Therapeutics-Files-Glybera-European-Marketing-Application-for-Re-examination.html http://www.amtbiopharma.com/news/29/182/Amsterdam-Molecular-Therapeutics-Appoints-Dr-Carlos-R-Camozzi-as-Chief-Medical-Officer.html Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer ... Wed, 06 Jul 2011 11:02:47 +0000 http://www.amtbiopharma.com/news/29/182/Amsterdam-Molecular-Therapeutics-Appoints-Dr-Carlos-R-Camozzi-as-Chief-Medical-Officer.html http://www.amtbiopharma.com/news/28/182/Amsterdam-Molecular-Therapeutics-Glybera-Significantly-Reduces-the-Risk-of-Pancreatitis-in-LPLD-Patients.html Amsterdam Molecular Therapeutics’ Glybera® Significantly Reduces the Risk of Pancreatitis in LPLD Patients ... Wed, 29 Jun 2011 11:01:39 +0000 http://www.amtbiopharma.com/news/28/182/Amsterdam-Molecular-Therapeutics-Glybera-Significantly-Reduces-the-Risk-of-Pancreatitis-in-LPLD-Patients.html http://www.amtbiopharma.com/news/31/182/Amsterdam-Molecular-Therapeutics-Receives-Opinion-on-Glybera-Marketing-Authorisation-Application.html Amsterdam Molecular Therapeutics Receives Opinion on Glybera Marketing Authorisation Application ... Fri, 24 Jun 2011 08:52:53 +0000 http://www.amtbiopharma.com/news/31/182/Amsterdam-Molecular-Therapeutics-Receives-Opinion-on-Glybera-Marketing-Authorisation-Application.html http://www.amtbiopharma.com/news/103/182/AMT-s-Cooperative-Research-and-Development-Agreement-With-NIH-to-Boost-Production-Capacity.html AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity ... Thu, 26 May 2011 13:46:53 +0000 http://www.amtbiopharma.com/news/103/182/AMT-s-Cooperative-Research-and-Development-Agreement-With-NIH-to-Boost-Production-Capacity.html http://www.amtbiopharma.com/news/32/182/AMT-Research-Demonstrates-AAV-Delivery-May-Be-Key-Success-Factor-for-Therapeutic-Promise-of-RNAi.html AMT Research Demonstrates AAV Delivery May Be Key Success Factor for Therapeutic Promise of RNAi ... Mon, 23 May 2011 08:08:37 +0000 http://www.amtbiopharma.com/news/32/182/AMT-Research-Demonstrates-AAV-Delivery-May-Be-Key-Success-Factor-for-Therapeutic-Promise-of-RNAi.html http://www.amtbiopharma.com/news/33/182/AMT-Presents-Data-Supporting-Role-of-Chylomicron-Clearance-as-Marker-for-Glybera-Efficacy.html AMT Presents Data Supporting Role of Chylomicron Clearance as Marker for Glybera Efficacy ... Fri, 20 May 2011 08:14:19 +0000 http://www.amtbiopharma.com/news/33/182/AMT-Presents-Data-Supporting-Role-of-Chylomicron-Clearance-as-Marker-for-Glybera-Efficacy.html http://www.amtbiopharma.com/news/34/182/AMT-Provides-Business-Update-for-the-First-Quarter.html AMT Provides Business Update for the First Quarter ... Thu, 19 May 2011 08:17:11 +0000 http://www.amtbiopharma.com/news/34/182/AMT-Provides-Business-Update-for-the-First-Quarter.html http://www.amtbiopharma.com/news/35/182/AMT-Provides-Status-Update-on-Glybera.html AMT Provides Status Update on Glybera ... Tue, 10 May 2011 08:21:03 +0000 http://www.amtbiopharma.com/news/35/182/AMT-Provides-Status-Update-on-Glybera.html http://www.amtbiopharma.com/news/36/182/AMT-Notice-of-Annual-General-Meeting.html AMT Notice of Annual General Meeting ... Wed, 23 Mar 2011 08:27:44 +0000 http://www.amtbiopharma.com/news/36/182/AMT-Notice-of-Annual-General-Meeting.html http://www.amtbiopharma.com/news/37/182/AMT-receives-grant-from-Dutch-parents-organization-for-Duchenne-Muscular-Dystrophy-gene-therapy.html AMT receives grant from Dutch parents organization for Duchenne Muscular Dystrophy gene therapy ... Mon, 07 Mar 2011 08:29:50 +0000 http://www.amtbiopharma.com/news/37/182/AMT-receives-grant-from-Dutch-parents-organization-for-Duchenne-Muscular-Dystrophy-gene-therapy.html http://www.amtbiopharma.com/news/44/182/Amsterdam-Molecular-Therapeutics-Reports-Full-Year-Results-2010.html Amsterdam Molecular Therapeutics Reports Full Year Results 2010 ... Wed, 16 Feb 2011 18:31:25 +0000 http://www.amtbiopharma.com/news/44/182/Amsterdam-Molecular-Therapeutics-Reports-Full-Year-Results-2010.html http://www.amtbiopharma.com/news/45/182/AMT-to-Release-Full-Year-2010-Results-on-Wednesday-February-16-2011.html AMT to Release Full Year 2010 Results on Wednesday February 16, 2011 ... Tue, 08 Feb 2011 18:43:56 +0000 http://www.amtbiopharma.com/news/45/182/AMT-to-Release-Full-Year-2010-Results-on-Wednesday-February-16-2011.html http://www.amtbiopharma.com/news/46/182/AMT-Receives-1-1-Million-Funding-for-Acute-Intermittent-Porphyria-Gene-Therapy-as-Part-of-EU-Consortium-Grant.html AMT Receives €1.1 Million Funding for Acute Intermittent Porphyria Gene Therapy as Part of EU Consortium Grant ... Mon, 31 Jan 2011 18:52:07 +0000 http://www.amtbiopharma.com/news/46/182/AMT-Receives-1-1-Million-Funding-for-Acute-Intermittent-Porphyria-Gene-Therapy-as-Part-of-EU-Consortium-Grant.html http://www.amtbiopharma.com/news/47/182/AMT-to-Supply-cGMP-Manufacturing-to-Consortium-Led-by-Institut-Pasteur-for-Development-of-Sanfilippo-B-Gene-Therapy-Product.html AMT to Supply cGMP Manufacturing to Consortium Led by Institut Pasteur for Development of Sanfilippo B Gene Therapy Product ... Mon, 10 Jan 2011 22:07:01 +0000 http://www.amtbiopharma.com/news/47/182/AMT-to-Supply-cGMP-Manufacturing-to-Consortium-Led-by-Institut-Pasteur-for-Development-of-Sanfilippo-B-Gene-Therapy-Product.html http://www.amtbiopharma.com/news/48/182/AMT-Announces-that-Steven-H-Holtzman-Has-Resigned-as-a-Member-of-the-Supervisory-Board-Due-to-Appointment-at-Biogen-Idec.html AMT Announces that Steven H. Holtzman Has Resigned as a Member of the Supervisory Board Due to Appointment at Biogen Idec ... Thu, 06 Jan 2011 22:21:23 +0000 http://www.amtbiopharma.com/news/48/182/AMT-Announces-that-Steven-H-Holtzman-Has-Resigned-as-a-Member-of-the-Supervisory-Board-Due-to-Appointment-at-Biogen-Idec.html http://www.amtbiopharma.com/news/49/182/AMT-Provides-Business-Update-for-the-Third-Quarter.html AMT Provides Business Update for the Third Quarter ... Thu, 18 Nov 2010 22:27:25 +0000 http://www.amtbiopharma.com/news/49/182/AMT-Provides-Business-Update-for-the-Third-Quarter.html http://www.amtbiopharma.com/news/50/182/Amsterdam-Molecular-Therapeutics-Successfully-Lowers-Cholesterol-In-Vivo-with-Enhanced-Novel-MicroRNA-AAV-Gene.html Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo with Enhanced Novel MicroRNA AAV Gene ... Mon, 25 Oct 2010 22:33:28 +0000 http://www.amtbiopharma.com/news/50/182/Amsterdam-Molecular-Therapeutics-Successfully-Lowers-Cholesterol-In-Vivo-with-Enhanced-Novel-MicroRNA-AAV-Gene.html http://www.amtbiopharma.com/news/58/182/AMT-s-Partner-Progenika-Receives-CE-Mark-for-First-DNA-Chip-to-Detect-Mutations-in-Lipoprotein-Lipase-LPL-Gene.html AMT’s Partner Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene ... Tue, 28 Sep 2010 20:29:25 +0000 http://www.amtbiopharma.com/news/58/182/AMT-s-Partner-Progenika-Receives-CE-Mark-for-First-DNA-Chip-to-Detect-Mutations-in-Lipoprotein-Lipase-LPL-Gene.html http://www.amtbiopharma.com/news/59/182/Prognika-Receives-CE-Mark-for-first-DNA-Chip-to-Detect-Mutations.html Prognika Receives CE Mark for first DNA Chip to Detect Mutations ... Mon, 27 Sep 2010 20:34:53 +0000 http://www.amtbiopharma.com/news/59/182/Prognika-Receives-CE-Mark-for-first-DNA-Chip-to-Detect-Mutations.html http://www.amtbiopharma.com/news/60/182/AMT-receives-orphan-drug-designation-from-the-U-S-Food-and-Drug-Administration-Duchenne-Muscular-Dystrophy-gen.html AMT receives orphan drug designation from the U.S. Food and Drug Administration Duchenne Muscular Dystrophy gen ... Fri, 24 Sep 2010 20:49:24 +0000 http://www.amtbiopharma.com/news/60/182/AMT-receives-orphan-drug-designation-from-the-U-S-Food-and-Drug-Administration-Duchenne-Muscular-Dystrophy-gen.html http://www.amtbiopharma.com/news/61/182/AMT-s-EGM-Passes-All-Resolutions-and-Strengthens-Supervisory-Board.html AMT’s EGM Passes All Resolutions and Strengthens Supervisory Board ... Mon, 20 Sep 2010 21:03:44 +0000 http://www.amtbiopharma.com/news/61/182/AMT-s-EGM-Passes-All-Resolutions-and-Strengthens-Supervisory-Board.html http://www.amtbiopharma.com/news/62/182/Amsterdam-Molecular-Therapeutics-Reports-Half-Year-Results.html Amsterdam Molecular Therapeutics Reports Half-Year Results ... Tue, 31 Aug 2010 21:17:52 +0000 http://www.amtbiopharma.com/news/62/182/Amsterdam-Molecular-Therapeutics-Reports-Half-Year-Results.html http://www.amtbiopharma.com/news/64/182/AMT-s-Marketing-Authorisation-Application-for-Glybera-Progressing-on-schedule.html AMT’s Marketing Authorisation Application for Glybera® Progressing on schedule ... Wed, 18 Aug 2010 21:46:08 +0000 http://www.amtbiopharma.com/news/64/182/AMT-s-Marketing-Authorisation-Application-for-Glybera-Progressing-on-schedule.html http://www.amtbiopharma.com/news/63/182/Announcement-on-the-Publication-of-the-Q2-2010.html Announcement on the Publication of the Q2, 2010 ... Wed, 18 Aug 2010 21:43:36 +0000 http://www.amtbiopharma.com/news/63/182/Announcement-on-the-Publication-of-the-Q2-2010.html http://www.amtbiopharma.com/news/65/182/AMT-nominates-three-high-profile-executives-to-the-Supervisory-Board-and-expands-Management.html AMT nominates three high profile executives to the Supervisory Board and expands Management ... Mon, 09 Aug 2010 21:51:44 +0000 http://www.amtbiopharma.com/news/65/182/AMT-nominates-three-high-profile-executives-to-the-Supervisory-Board-and-expands-Management.html http://www.amtbiopharma.com/news/66/182/Amsterdam-Molecular-Therapeutics-Reports-Positive-New-Clinical-Data-from-Glybera-Study.html Amsterdam Molecular Therapeutics Reports Positive New Clinical Data from Glybera Study ... Fri, 04 Jun 2010 21:58:23 +0000 http://www.amtbiopharma.com/news/66/182/Amsterdam-Molecular-Therapeutics-Reports-Positive-New-Clinical-Data-from-Glybera-Study.html http://www.amtbiopharma.com/news/67/182/Amsterdam-Molecular-Therapeutics-Reports-Promising-Data-from-Cholesterol-Lowering-Gene-Therapy-Study.html Amsterdam Molecular Therapeutics Reports Promising Data from Cholesterol Lowering Gene Therapy Study ... Fri, 21 May 2010 22:04:43 +0000 http://www.amtbiopharma.com/news/67/182/Amsterdam-Molecular-Therapeutics-Reports-Promising-Data-from-Cholesterol-Lowering-Gene-Therapy-Study.html http://www.amtbiopharma.com/news/68/182/AMT-provides-business-update-for-the-first-quarter-2010.html AMT provides business update for the first quarter 2010 ... Wed, 19 May 2010 22:09:56 +0000 http://www.amtbiopharma.com/news/68/182/AMT-provides-business-update-for-the-first-quarter-2010.html http://www.amtbiopharma.com/news/69/182/Professor-Sander-van-Deventer-appointed-to-Supervisory-Board-of-AMT.html Professor Sander van Deventer appointed to Supervisory Board of AMT ... Thu, 06 May 2010 08:10:56 +0000 http://www.amtbiopharma.com/news/69/182/Professor-Sander-van-Deventer-appointed-to-Supervisory-Board-of-AMT.html http://www.amtbiopharma.com/news/70/182/Start-of-Phase-I-II-Gene-Therapy-Clinical-Trial-for-Hemophilia-B.html Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B ... Wed, 10 Mar 2010 08:19:26 +0000 http://www.amtbiopharma.com/news/70/182/Start-of-Phase-I-II-Gene-Therapy-Clinical-Trial-for-Hemophilia-B.html http://www.amtbiopharma.com/news/71/182/Amsterdam-Molecular-Therapeutics-Reports-Full-Year-Results-2009.html Amsterdam Molecular Therapeutics Reports Full Year Results 2009 ... Wed, 24 Feb 2010 08:27:16 +0000 http://www.amtbiopharma.com/news/71/182/Amsterdam-Molecular-Therapeutics-Reports-Full-Year-Results-2009.html http://www.amtbiopharma.com/news/72/182/EMA-starts-formal-review-of-Glybera-dossier.html EMA starts formal review of Glybera dossier ... Mon, 25 Jan 2010 08:34:37 +0000 http://www.amtbiopharma.com/news/72/182/EMA-starts-formal-review-of-Glybera-dossier.html http://www.amtbiopharma.com/news/73/182/AMT-submits-its-lead-product-Glybera-Application-for-Marketing-Authorisation-Application-to-EMA.html AMT submits its lead product Glybera Application for Marketing Authorisation Application to EMA ... Mon, 11 Jan 2010 08:36:33 +0000 http://www.amtbiopharma.com/news/73/182/AMT-submits-its-lead-product-Glybera-Application-for-Marketing-Authorisation-Application-to-EMA.html http://www.amtbiopharma.com/news/74/182/AMT-Receives-Innovation-Credit-from-Dutch-Government-for-Duchenne-Muscular-Dystrophy.html AMT Receives Innovation Credit from Dutch Government for Duchenne Muscular Dystrophy ... Wed, 06 Jan 2010 08:39:30 +0000 http://www.amtbiopharma.com/news/74/182/AMT-Receives-Innovation-Credit-from-Dutch-Government-for-Duchenne-Muscular-Dystrophy.html http://www.amtbiopharma.com/news/75/182/Amsterdam-Molecular-Therapeutics-AMT-successfully-raises-EUR-5-million-via-a-Convertible-Bond-issue-with-shareholder-Forbion.html Amsterdam Molecular Therapeutics (AMT) successfully raises EUR 5 million via a Convertible Bond issue with shareholder Forbion ... Wed, 16 Dec 2009 08:48:43 +0000 http://www.amtbiopharma.com/news/75/182/Amsterdam-Molecular-Therapeutics-AMT-successfully-raises-EUR-5-million-via-a-Convertible-Bond-issue-with-shareholder-Forbion.html http://www.amtbiopharma.com/news/76/182/AMT-Announces-Management-Changes-in-light-of-refocused-strategey.html AMT Announces Management Changes in light of refocused strategey ... Wed, 02 Dec 2009 08:52:05 +0000 http://www.amtbiopharma.com/news/76/182/AMT-Announces-Management-Changes-in-light-of-refocused-strategey.html http://www.amtbiopharma.com/news/77/182/AMT-Provides-Business-Update-for-the-Third-Quarter-2009.html AMT Provides Business Update for the Third Quarter 2009 ... Wed, 18 Nov 2009 09:34:02 +0000 http://www.amtbiopharma.com/news/77/182/AMT-Provides-Business-Update-for-the-Third-Quarter-2009.html http://www.amtbiopharma.com/news/78/182/AMT-Successful-in-Preclinical-Treatment-of-DMD.html AMT Successful in Preclinical Treatment of DMD ... Wed, 11 Nov 2009 09:43:37 +0000 http://www.amtbiopharma.com/news/78/182/AMT-Successful-in-Preclinical-Treatment-of-DMD.html http://www.amtbiopharma.com/news/80/182/AMT-Uses-PimTim-to-Design-Packaging-for-Gene-Therapy.html AMT Uses PimTim to Design Packaging for Gene Therapy ... Thu, 29 Oct 2009 09:58:57 +0000 http://www.amtbiopharma.com/news/80/182/AMT-Uses-PimTim-to-Design-Packaging-for-Gene-Therapy.html http://www.amtbiopharma.com/news/79/182/AMT-Starts-Development-LPLChip-TM-with-Progenika.html AMT Starts Development LPLChip(TM) with Progenika ... Thu, 29 Oct 2009 09:56:25 +0000 http://www.amtbiopharma.com/news/79/182/AMT-Starts-Development-LPLChip-TM-with-Progenika.html http://www.amtbiopharma.com/news/81/182/AMT-Receives-EMEA-Orphan-Drug-Designation-for-Duchenne-Muscular-Dystrophy.html AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy ... Tue, 13 Oct 2009 10:00:39 +0000 http://www.amtbiopharma.com/news/81/182/AMT-Receives-EMEA-Orphan-Drug-Designation-for-Duchenne-Muscular-Dystrophy.html http://www.amtbiopharma.com/news/82/182/AMT-Appoints-New-Chief-Executive-Officer.html AMT Appoints New Chief Executive Officer ... Thu, 24 Sep 2009 10:43:13 +0000 http://www.amtbiopharma.com/news/82/182/AMT-Appoints-New-Chief-Executive-Officer.html http://www.amtbiopharma.com/news/83/182/Amsterdam-Molecular-Therapeutics-Reports-Half-Year-Results-2009.html Amsterdam Molecular Therapeutics Reports Half Year Results 2009 ... Thu, 13 Aug 2009 10:47:47 +0000 http://www.amtbiopharma.com/news/83/182/Amsterdam-Molecular-Therapeutics-Reports-Half-Year-Results-2009.html http://www.amtbiopharma.com/news/84/182/Glybera-Shows-Long-Term-Health-Benefits.html Glybera Shows Long-Term Health Benefits ... Thu, 18 Jun 2009 10:50:11 +0000 http://www.amtbiopharma.com/news/84/182/Glybera-Shows-Long-Term-Health-Benefits.html http://www.amtbiopharma.com/news/85/182/AMT-Receives-EMEA-Orphan-Drug-Designation-for-Acute-Intermittent-Porphyria.html AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria ... Thu, 28 May 2009 10:56:30 +0000 http://www.amtbiopharma.com/news/85/182/AMT-Receives-EMEA-Orphan-Drug-Designation-for-Acute-Intermittent-Porphyria.html http://www.amtbiopharma.com/news/86/182/AMT-issues-business-update-for-first-quarter-2009.html AMT issues business update for first quarter 2009 ... Tue, 19 May 2009 10:59:02 +0000 http://www.amtbiopharma.com/news/86/182/AMT-issues-business-update-for-first-quarter-2009.html http://www.amtbiopharma.com/news/87/182/AMT-Starts-Preregistration-Trial-for-Glybera.html AMT Starts Preregistration Trial for Glybera ... Thu, 07 May 2009 11:02:07 +0000 http://www.amtbiopharma.com/news/87/182/AMT-Starts-Preregistration-Trial-for-Glybera.html http://www.amtbiopharma.com/news/88/182/Amsterdam-Molecular-Therapeutics-Reports-Full-Year-Results-2008.html Amsterdam Molecular Therapeutics Reports Full Year Results 2008 ... Tue, 24 Feb 2009 11:04:33 +0000 http://www.amtbiopharma.com/news/88/182/Amsterdam-Molecular-Therapeutics-Reports-Full-Year-Results-2008.html http://www.amtbiopharma.com/news/89/182/AMT-Glybera-Lowers-Pancreatitis-Incidence-Significantly.html AMT: Glybera Lowers Pancreatitis Incidence Significantly ... Wed, 28 Jan 2009 11:07:33 +0000 http://www.amtbiopharma.com/news/89/182/AMT-Glybera-Lowers-Pancreatitis-Incidence-Significantly.html http://www.amtbiopharma.com/news/90/182/AMT-CEO-Ronald-Lorijn-Steps-Down.html AMT CEO Ronald Lorijn Steps Down ... Thu, 22 Jan 2009 11:09:12 +0000 http://www.amtbiopharma.com/news/90/182/AMT-CEO-Ronald-Lorijn-Steps-Down.html http://www.amtbiopharma.com/news/91/182/AMT-intends-to-incorporate-additional-data-to-its-Marketing-Authorization-Dossier-for-Glybera.html AMT intends to incorporate additional data to its Marketing Authorization Dossier for Glybera ... Fri, 03 Oct 2008 11:12:52 +0000 http://www.amtbiopharma.com/news/91/182/AMT-intends-to-incorporate-additional-data-to-its-Marketing-Authorization-Dossier-for-Glybera.html http://www.amtbiopharma.com/news/92/182/AMT-Obtains-License-to-Amgen-s-GDNF-Gene-to-Develop-Treatment-for-Parkinson-s-Disease-with-AMT-s-Proprietary-Gene-Therapy-Platform.html AMT Obtains License to Amgen’s GDNF Gene to Develop Treatment for Parkinson’s Disease with AMT’s Proprietary Gene Therapy Platform ... Thu, 18 Sep 2008 11:13:56 +0000 http://www.amtbiopharma.com/news/92/182/AMT-Obtains-License-to-Amgen-s-GDNF-Gene-to-Develop-Treatment-for-Parkinson-s-Disease-with-AMT-s-Proprietary-Gene-Therapy-Platform.html http://www.amtbiopharma.com/news/96/182/Roushan-Khandaker-Group-Initiates-Coverage-of-AMT-Price-Target-of-EUR-16-86-over-an-18-to-36-Month-Period.html Roushan Khandaker Group Initiates Coverage of AMT. Price Target of EUR 16.86 over an 18 to 36 Month Period ... Tue, 16 Sep 2008 11:42:13 +0000 http://www.amtbiopharma.com/news/96/182/Roushan-Khandaker-Group-Initiates-Coverage-of-AMT-Price-Target-of-EUR-16-86-over-an-18-to-36-Month-Period.html http://www.amtbiopharma.com/news/51/182/Amsterdam-Molecular-Therapeutics-Licenses-Additional-Novel-Gene-Therapy-Vectors-from-National-Institutes-of-Health-and-Gains-US-Patent-Protection-for-Proprietary-AAV-Intellectual-Property.html AMT Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health and Gains US Patent Protection for Proprietary AAV Intellectual Property ... Sat, 06 Sep 2008 06:58:31 +0000 http://www.amtbiopharma.com/news/51/182/Amsterdam-Molecular-Therapeutics-Licenses-Additional-Novel-Gene-Therapy-Vectors-from-National-Institutes-of-Health-and-Gains-US-Patent-Protection-for-Proprietary-AAV-Intellectual-Property.html http://www.amtbiopharma.com/news/97/182/Amsterdam-Molecular-Therapeutics-Reports-Half-Year-Results-2008.html Amsterdam Molecular Therapeutics Reports Half Year Results 2008 ... Wed, 13 Aug 2008 11:47:03 +0000 http://www.amtbiopharma.com/news/97/182/Amsterdam-Molecular-Therapeutics-Reports-Half-Year-Results-2008.html http://www.amtbiopharma.com/news/98/182/AMT-Appoints-Director-Global-Marketing-and-Sales.html AMT Appoints Director Global Marketing and Sales ... Thu, 17 Jul 2008 11:49:09 +0000 http://www.amtbiopharma.com/news/98/182/AMT-Appoints-Director-Global-Marketing-and-Sales.html http://www.amtbiopharma.com/news/99/182/AMT-Starts-Collaboration-With-St-Jude-Children-s-Research-Hospital-on-Gene-Therapy-for-Hemophilia-B-Company-Accesses-Exclusive-Commercial-Rights-to-Final-Therapy.html AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy ... Tue, 15 Jul 2008 11:52:34 +0000 http://www.amtbiopharma.com/news/99/182/AMT-Starts-Collaboration-With-St-Jude-Children-s-Research-Hospital-on-Gene-Therapy-for-Hemophilia-B-Company-Accesses-Exclusive-Commercial-Rights-to-Final-Therapy.html http://www.amtbiopharma.com/news/100/182/AMT-prepares-for-submission-of-Marketing-Authorization-Dossier-for-AMT-011-Glybera.html AMT prepares for submission of Marketing Authorization Dossier for AMT-011 (Glybera®) ... Fri, 13 Jun 2008 11:54:04 +0000 http://www.amtbiopharma.com/news/100/182/AMT-prepares-for-submission-of-Marketing-Authorization-Dossier-for-AMT-011-Glybera.html http://www.amtbiopharma.com/news/101/182/AMT-makes-important-advance-in-the-development-of-its-gene-therapy-for-Hemophilia-B---Company-Accesses-Technology-to-Prevent-Immune-Response.html AMT makes important advance in the development of its gene therapy for Hemophilia B - Company Accesses Technology to Prevent Immune Response ... Tue, 10 Jun 2008 12:56:26 +0000 http://www.amtbiopharma.com/news/101/182/AMT-makes-important-advance-in-the-development-of-its-gene-therapy-for-Hemophilia-B---Company-Accesses-Technology-to-Prevent-Immune-Response.html http://www.amtbiopharma.com/news/102/182/AMT-Announces-Positive-Interim-Clinical-Data-on-its-Lead-Product-AMT-011.html AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011 ... Fri, 30 May 2008 13:44:44 +0000 http://www.amtbiopharma.com/news/102/182/AMT-Announces-Positive-Interim-Clinical-Data-on-its-Lead-Product-AMT-011.html http://www.amtbiopharma.com/news/104/182/AMT-Accesses-Technology-for-Treatment-of-Duchenne-Muscular-Dystrophy.html AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy ... Thu, 22 May 2008 13:50:23 +0000 http://www.amtbiopharma.com/news/104/182/AMT-Accesses-Technology-for-Treatment-of-Duchenne-Muscular-Dystrophy.html http://www.amtbiopharma.com/news/105/182/Amsterdam-Molecular-Therapeutics-part-of-Next-Biotech-Index.html Amsterdam Molecular Therapeutics part of Next Biotech Index ... Tue, 08 Apr 2008 13:54:25 +0000 http://www.amtbiopharma.com/news/105/182/Amsterdam-Molecular-Therapeutics-part-of-Next-Biotech-Index.html http://www.amtbiopharma.com/news/106/182/Amsterdam-Molecular-Therapeutics-to-Appoint-George-Morstyn-to-Supervisory-Board.html Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board ... Wed, 02 Apr 2008 13:55:39 +0000 http://www.amtbiopharma.com/news/106/182/Amsterdam-Molecular-Therapeutics-to-Appoint-George-Morstyn-to-Supervisory-Board.html http://www.amtbiopharma.com/news/107/182/Amsterdam-Molecular-Therapeutics-to-appoint-Alexander-Ribbink-to-Supervisory-Board.html Amsterdam Molecular Therapeutics to appoint Alexander Ribbink to Supervisory Board ... Thu, 20 Mar 2008 13:57:26 +0000 http://www.amtbiopharma.com/news/107/182/Amsterdam-Molecular-Therapeutics-to-appoint-Alexander-Ribbink-to-Supervisory-Board.html http://www.amtbiopharma.com/news/108/182/Amsterdam-Molecular-Therapeutics-Reports-Full-Year-Results-2007.html Amsterdam Molecular Therapeutics Reports Full Year Results 2007 ... Wed, 20 Feb 2008 14:05:21 +0000 http://www.amtbiopharma.com/news/108/182/Amsterdam-Molecular-Therapeutics-Reports-Full-Year-Results-2007.html http://www.amtbiopharma.com/news/110/182/AMT-s-Lead-Product-Poised-to-Address-Major-Liver-Disease.html AMT's Lead Product Poised to Address Major Liver Disease ... Mon, 28 Jan 2008 14:10:08 +0000 http://www.amtbiopharma.com/news/110/182/AMT-s-Lead-Product-Poised-to-Address-Major-Liver-Disease.html http://www.amtbiopharma.com/news/109/182/Amsterdam-Molecular-Therapeutics-to-Appoint-Philippe-van-Holle-Celgene-to-Supervisory-Board.html Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board ... Mon, 21 Jan 2008 14:08:59 +0000 http://www.amtbiopharma.com/news/109/182/Amsterdam-Molecular-Therapeutics-to-Appoint-Philippe-van-Holle-Celgene-to-Supervisory-Board.html http://www.amtbiopharma.com/news/93/182/AMT-Initiates-Program-for-Late-Stage-Liver-Cirrhosis-and-Reports-Strong-Progress-in-AMT-011.html AMT Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 ... Tue, 27 Nov 2007 11:30:49 +0000 http://www.amtbiopharma.com/news/93/182/AMT-Initiates-Program-for-Late-Stage-Liver-Cirrhosis-and-Reports-Strong-Progress-in-AMT-011.html http://www.amtbiopharma.com/news/94/182/Amsterdam-Molecular-Therapeutics-Reports-Half-Year-Results-2007.html Amsterdam Molecular Therapeutics Reports Half Year Results 2007 ... Wed, 29 Aug 2007 11:34:25 +0000 http://www.amtbiopharma.com/news/94/182/Amsterdam-Molecular-Therapeutics-Reports-Half-Year-Results-2007.html http://www.amtbiopharma.com/news/111/182/Amsterdam-Molecular-Therapeutics-AMT-Holding-N-V---Stabilization-Notice.html Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Stabilization Notice ... Tue, 24 Jul 2007 16:22:23 +0000 http://www.amtbiopharma.com/news/111/182/Amsterdam-Molecular-Therapeutics-AMT-Holding-N-V---Stabilization-Notice.html http://www.amtbiopharma.com/news/112/182/Amsterdam-Molecular-Therapeutics-raises-additional-EUR-5-67-million-in-IPO-following-partial-exercise-over-allotment-option.html Amsterdam Molecular Therapeutics raises additional EUR 5.67 million in IPO following partial exercise over-allotment option ... Wed, 18 Jul 2007 17:00:39 +0000 http://www.amtbiopharma.com/news/112/182/Amsterdam-Molecular-Therapeutics-raises-additional-EUR-5-67-million-in-IPO-following-partial-exercise-over-allotment-option.html http://www.amtbiopharma.com/news/113/182/Amsterdam-Molecular-Therapeutics-announces-pricing-of-Initial-Public-Offering-IPO-on-Euronext-Amaerdam.html Amsterdam Molecular Therapeutics announces pricing of Initial Public Offering (IPO) on Euronext Amaerdam ... Wed, 20 Jun 2007 17:04:37 +0000 http://www.amtbiopharma.com/news/113/182/Amsterdam-Molecular-Therapeutics-announces-pricing-of-Initial-Public-Offering-IPO-on-Euronext-Amaerdam.html http://www.amtbiopharma.com/news/114/182/Correction-of-certain-information-in-the-media-relating-to-the-offering-of-new-shares-Amsterdam-Molecular-Therapeutics-AMT-Holding-N-V.html Correction of certain information in the media relating to the offering of new shares Amsterdam Molecular Therapeutics (AMT) Holding N.V. ... Sun, 17 Jun 2007 17:15:13 +0000 http://www.amtbiopharma.com/news/114/182/Correction-of-certain-information-in-the-media-relating-to-the-offering-of-new-shares-Amsterdam-Molecular-Therapeutics-AMT-Holding-N-V.html http://www.amtbiopharma.com/news/115/182/Amsterdam-Molecular-Therapeutics-announces-launch-of-Initial-Public-Offering-IPO-on-Euronext-Amsterdam.html Amsterdam Molecular Therapeutics announces launch of Initial Public Offering (IPO) on Euronext Amsterdam ... Wed, 06 Jun 2007 17:18:27 +0000 http://www.amtbiopharma.com/news/115/182/Amsterdam-Molecular-Therapeutics-announces-launch-of-Initial-Public-Offering-IPO-on-Euronext-Amsterdam.html http://www.amtbiopharma.com/news/116/182/AMT-Receives-Orphan-Drug-Designation-from-FDA-for-AMT-011.html AMT Receives Orphan Drug Designation from FDA for AMT 011 ... Mon, 04 Jun 2007 15:10:23 +0000 http://www.amtbiopharma.com/news/116/182/AMT-Receives-Orphan-Drug-Designation-from-FDA-for-AMT-011.html http://www.amtbiopharma.com/news/117/182/AMT-Presents-Positive-Results-of-Phase-I-II-Study-with-Lead-Product-at-Annual-Meeting-of-American-Society-of-Gene-Therapy.html AMT Presents Positive Results of Phase I/II Study with Lead Product at Annual Meeting of American Society of Gene Therapy ... Thu, 31 May 2007 15:11:25 +0000 http://www.amtbiopharma.com/news/117/182/AMT-Presents-Positive-Results-of-Phase-I-II-Study-with-Lead-Product-at-Annual-Meeting-of-American-Society-of-Gene-Therapy.html http://www.amtbiopharma.com/news/118/182/Amsterdam-Molecular-Therapeutics-Appoints-Ferdinand-Verdonck-as-Chairman-of-the-Supervisory-Board.html Amsterdam Molecular Therapeutics Appoints Ferdinand Verdonck as Chairman of the Supervisory Board ... Thu, 24 May 2007 15:12:47 +0000 http://www.amtbiopharma.com/news/118/182/Amsterdam-Molecular-Therapeutics-Appoints-Ferdinand-Verdonck-as-Chairman-of-the-Supervisory-Board.html http://www.amtbiopharma.com/news/119/182/Amsterdam-Molecular-Therapeutics-announces-intention-to-launch-an-Initial-Public-Offering-IPO-on-Euronext-Amsterdam.html Amsterdam Molecular Therapeutics announces intention to launch an Initial Public Offering (IPO) on Euronext Amsterdam ... Mon, 14 May 2007 15:17:18 +0000 http://www.amtbiopharma.com/news/119/182/Amsterdam-Molecular-Therapeutics-announces-intention-to-launch-an-Initial-Public-Offering-IPO-on-Euronext-Amsterdam.html http://www.amtbiopharma.com/news/120/182/Amsterdam-Molecular-Therapeutics-BV-receives-global-rights-to-develop-and-commercialize-AMT-020-for-acute-intermittent-porphyria.html Amsterdam Molecular Therapeutics BV receives global rights to develop and commercialize AMT-020 for acute intermittent porphyria ... Wed, 28 Feb 2007 15:19:08 +0000 http://www.amtbiopharma.com/news/120/182/Amsterdam-Molecular-Therapeutics-BV-receives-global-rights-to-develop-and-commercialize-AMT-020-for-acute-intermittent-porphyria.html http://www.amtbiopharma.com/news/121/182/Amsterdam-Molecular-Therapeutics-BV-enters-research-collaboration-with-the-University-of-Barcelona.html Amsterdam Molecular Therapeutics BV enters research collaboration with the University of Barcelona ... Thu, 15 Feb 2007 15:20:15 +0000 http://www.amtbiopharma.com/news/121/182/Amsterdam-Molecular-Therapeutics-BV-enters-research-collaboration-with-the-University-of-Barcelona.html